FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4368365009> ?p ?o ?g. }

• W4368365009 endingPage "S99" @default.
• W4368365009 startingPage "S99" @default.
• W4368365009 abstract "Alemtuzumab (ALZ) is an anti-CD52 monoclonal antibody effective in treating relapsing-remitting Multiple Sclerosis (MS). ALZ is hypothesized to augment immune function due to mature lymphocyte depletion; it may also predispose patients to secondary autoimmune disorders during the immune system recovery phase, with thyroid dysfunction occurring in up to 33%. We a case of a woman with MS who developed Hashimoto’s thyroiditis followed by Graves’ disease after ALZ use. A 43-year-old woman with MS was referred for management of hyperthyroidism after experiencing 1 year of palpitations, insomnia, and tremors. She completed two doses of ALZ nineteen months apart. Nine months after her 2nd ALZ dose, she developed hypothyroidism (TSH 38 mIU/L, TPO 856 IU/L, and low FT4 0.2ng/dL); she was treated to euthyroidism with levothyroxine. Sixteen months after her 2nd dose, she developed hyperthyroidism, persisting after levothyroxine cessation: TSH 0.02 mIU/L, FT4 1.9ng/dL, FT3 7.4pg/mL, TRAb 9.6, TSI 385, and TPO 83 IU/L. Her Graves’ disease course was complicated by the development of mild unilateral proptosis and diplopia. Past medical history included neurogenic bladder and anxiety, treated with mirabegron and alprazolam. Family history was notable for thyroidectomy in her mother for unknown indication. Physical exam showed stable vitals, mild active thyroid eye disease, goiter, and fine bilateral hand tremor. She was initially treated with methimazole, but unfortunately developed significant hepatotoxicity. She was recommended for total thyroidectomy, which she underwent without complication following preparation with potassium iodide. This case highlights an interesting presentation of co-existing autoimmune thyroid disorders in an ALZ-treated patient. ALZ has a rapid and long-lasting effect on the immune system, leading to qualitative and quantitative lymphocyte changes. ALZ induced Graves’ disease (AIGD) is the most common thyroid disorder, followed by Hashimoto’s thyroiditis & silent thyroiditis at 63%, 15%, & 9%, respectively. Most of those with AIGD had overt symptoms, and 10% reported ophthalmopathy. They peak around 28 months after the last dose, concurring with the B cell slow recovery phase. Over half of patients with AIGD required anti-thyroid medications (56%), 22% underwent radioactive iodine, and 11% underwent thyroidectomy. Interestingly, MS patients who developed AIGD had better overall MS disease prognosis. The frequency of ALZ-associated thyroid disease underscores the importance of routine thyroid function monitoring every 3 months following ALZ, and a provision of thyroid education materials for earlier identification of thyroid disorders." @default.
• W4368365009 created "2023-05-05" @default.
• W4368365009 creator A5027031255 @default.
• W4368365009 creator A5049968160 @default.
• W4368365009 creator A5074738537 @default.
• W4368365009 date "2023-05-01" @default.
• W4368365009 modified "2023-09-23" @default.
• W4368365009 title "Abstract #1400968: A Case of Co-Existing Alemtuzumab-Induced Thyroid Disorders" @default.
• W4368365009 doi "https://doi.org/10.1016/j.eprac.2023.03.220" @default.
• W4368365009 hasPublicationYear "2023" @default.
• W4368365009 type Work @default.
• W4368365009 citedByCount "1" @default.
• W4368365009 countsByYear W43683650092023 @default.
• W4368365009 crossrefType "journal-article" @default.
• W4368365009 hasAuthorship W4368365009A5027031255 @default.
• W4368365009 hasAuthorship W4368365009A5049968160 @default.
• W4368365009 hasAuthorship W4368365009A5074738537 @default.
• W4368365009 hasBestOaLocation W43683650091 @default.
• W4368365009 hasConcept C126322002 @default.
• W4368365009 hasConcept C187212893 @default.
• W4368365009 hasConcept C2775883008 @default.
• W4368365009 hasConcept C2776652619 @default.
• W4368365009 hasConcept C2778696486 @default.
• W4368365009 hasConcept C2779015954 @default.
• W4368365009 hasConcept C2780176905 @default.
• W4368365009 hasConcept C2911091166 @default.
• W4368365009 hasConcept C526584372 @default.
• W4368365009 hasConcept C71924100 @default.
• W4368365009 hasConcept C90924648 @default.
• W4368365009 hasConceptScore W4368365009C126322002 @default.
• W4368365009 hasConceptScore W4368365009C187212893 @default.
• W4368365009 hasConceptScore W4368365009C2775883008 @default.
• W4368365009 hasConceptScore W4368365009C2776652619 @default.
• W4368365009 hasConceptScore W4368365009C2778696486 @default.
• W4368365009 hasConceptScore W4368365009C2779015954 @default.
• W4368365009 hasConceptScore W4368365009C2780176905 @default.
• W4368365009 hasConceptScore W4368365009C2911091166 @default.
• W4368365009 hasConceptScore W4368365009C526584372 @default.
• W4368365009 hasConceptScore W4368365009C71924100 @default.
• W4368365009 hasConceptScore W4368365009C90924648 @default.
• W4368365009 hasIssue "5" @default.
• W4368365009 hasLocation W43683650091 @default.
• W4368365009 hasOpenAccess W4368365009 @default.
• W4368365009 hasPrimaryLocation W43683650091 @default.
• W4368365009 hasRelatedWork W1510982470 @default.
• W4368365009 hasRelatedWork W2103317566 @default.
• W4368365009 hasRelatedWork W2121481979 @default.
• W4368365009 hasRelatedWork W2257623551 @default.
• W4368365009 hasRelatedWork W2298065614 @default.
• W4368365009 hasRelatedWork W2571186851 @default.
• W4368365009 hasRelatedWork W2794410138 @default.
• W4368365009 hasRelatedWork W3029058467 @default.
• W4368365009 hasRelatedWork W3192271674 @default.
• W4368365009 hasRelatedWork W4280623680 @default.
• W4368365009 hasVolume "29" @default.
• W4368365009 isParatext "false" @default.
• W4368365009 isRetracted "false" @default.
• W4368365009 workType "article" @default.